Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer (NCT04068649)
A Phase 2 Randomized Study With a Non-randomized Cohort : Assessing Single-Fraction SBRT Versus Standard Palliative Radiation in Patients With Metastatic Disease (ASTEROID)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Who can join: Review the eligibility criteria below.
Location: Roswell Park Cancer Institute — Buffalo, New York
Age range: 18 Years
🧪 Interventions in This Study
- Palliative Radiation Therapy (RADIATION)
- Quality-of-Life Assessment (OTHER)
- Questionnaire Administration (OTHER)
- Stereotactic Body Radiation Therapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Roswell Park Cancer Institute — Buffalo, New York
- The Cancer Institute at St. Francis Hospital — East Hills, New York
- Good Samaritan Hospital — West Islip, New York
📞 Contact the Study Coordinator
Phone: (716) 845-3218
Email: Anurag.Singh@roswellpark.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Malignant Neoplasm
- Cryoablation for the Treatment of Metastatic Cancer — Houston, Texas
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) — Houston, Texas
- Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases — Houston, Texas
- NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies — La Jolla, California
- A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 — Baltimore, Maryland
Explore by condition: All Metastatic Malignant Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.